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Summary.-A highly hydrophobic alkylating agent, 1-N,N-bis(beta-bromoethyl)
amino-3-methylnaphthalene, given as the free drug in oil, cured a substantial pro-
portion of mice bearing the PC6 myeloma in the dose range 2-7 mg/kg. However,
these doses were toxic, and the LD50 was 6-7 mg/kg. When incorporated in liposomes,
similar curative effects were obtained at doses of 10-41 mg/kg without material
toxicity, even at the highest dose. Liposome entrapment therefore greatly increases
the therapeutic efficiency of this agent.
NUMEROUS STUDIES have been made of
the treatment of tumours of laboratory
animals by drugs carried in liposomes,
in the hope that this mode of delivery
would selectively increase drug uptake
by the tumour relative to normal tissues.
Although it has been shown that drug
incorporated in liposomes may have a
greater therapeutic effect than the same
amount of drug in free form, few investi-
gations have also compared the toxicities
of the 2 methods of drug delivery (for
review, see Kaye et al., 1980). Clearly,
there would be no therapeutic gain from
incorporating drug in liposomes if an
increase in therapeutic effect were accom-
panied by an equal (or greater) increase
in toxicity.
The effect of liposome entrapment on
the actions of a drug depends on many
factors, such as the rates of entry of drug-
containing liposomes into cells of different
types, and the rate of release of drug
from liposomes, both in cells and in the
circulation, and these will be determined,
inter alia, by liposome size and composi-
tion. There have been many studies of
the effects of these factors. However, one
important factor that has been relatively
neglected is the location of the drug in
the liposome, whether in the aqueous or
lipid phase or both. So far, in vivo studies
have concerned drugs such as metho-
trexate and cytosine arabinoside, which
are practically lipid-insoluble and pre-
sumably restricted to the water phase,
or actinomycin D and nitrogen mustard
which are both lipid- and water-soluble
and may be present in both phases. We
therefore carried out in vivo experiments
on the effects of a highly hydrophobic
alkylating agent, WB 4325 (1-N,N-bis
(beta-bromoethyl)amino-3-methylnaphth -
lene), either in free form dissolved in
oil, or in liposomes.
MATERIALS AND METHODS
Preparation of liposomes.-A modification
of the method of Batzri & Korn (1973) was
used. L-a-dimyristoyl phosphatidyl choline
(140 mg, Sigma), 40 mg ofcholesterol (Sigma)
and 20 mg of phosphatidic acid (Lipid Pro-
ducts) were dissolved in 8 ml Analar ethanol
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which had been saturated with N2 before
use. Tothis solution was added 2 mlofethanol
containing 20 mg WB 4325 (Ward Blenkinsop
Ltd.). 1 ml of the lipid-drug solution in
ethanol was rapidly injected beneath the
surface of 20 ml of N2-saturated 0-15M NaCl
kept at 60-65°C on a water-bath, using a
1 ml syringe and 21-gauge needle. Ten such
aliquots were pooled (210 ml) and concen-
trated in an Amicon cell, type 202, with an
Amicon XM 100A filter, using N2 at 8 lb/in2
pressure and constant stirring. When the
volume had been reduced to about 5 ml,
40 ml of 0415M NaCl was added and the
process continued to wash the liposomes.
Washing was carried out twice. The final
volume ( 7 ml) of liposome suspension was
centrifuged at 10,000 g for 15 min and the
supernatant used.
Measurement of liposome-bound drug.
Alkylating activity in the liposome suspen-
sion was measured as described earlier
(Berenbaum et al., 1973) using a modification
of the method of Hopwood & Stock (1971).
Liposome suspension (50,U) was mixed
with 0 3 ml ethanol, and then with 0-15 ml
0-15M saline and 1 ml Epstein's reagent
(1% 4(p-nitrobenzyl)pyridine in90°O ethylene
glycol/10% 0-5m acetate buffer, pH 4.6).
The tightly stoppered tube was placed on a
90°C water bath for 20 min. The reaction
was stopped by placing the tube on ice;
3 ml of 1:1 (v/v) acetone: triethylamine was
added with rapid mixing and the absorbance
of the solution at 555 lum read immediately.
The amount of drug was calculated from a
standard absorbance curve made with an
ethanol solution of WB 4325 diluted appro-
priately with saline before use.
Tumour.-The PC6 mouse myeloma, ob-
tained originally from Chester Beatty Re-
search Institute, Nwas passaged in male
BALB/c mice by s.c. injection of 106 viable
cells (viability was assessed by hydrolysis
of fluorescein diacetate and exclusion of
ethidium bromide).
Treatment was given as a single injection
to mice bearing 14-day-old tumours, which
were generally about 1 cm long and 0 7 cm
wide at the time of injection.
Treatment.-Tw%o methods of drug delivery
were compared. WB 4325 was dissolved in
arachis oil and given i.p. in 0-1 ml/10 g.
or it was given in liposomes, in a volume of
about 0 5-0 75/10 g, injected slowly i.v.
Measurement of therapeutic and toxic
effects.-The maximum and minimum tumour
diameters were measured in mm 3 x weekly,
and tumour volume calculated from the
formula:
7r2 Volume= 6 (M-0 7) (m-0.7)2
where M and m were the greatest and least
diameters, respectively; the average skin
thickness in these mice was 0-7 mm.
Two measures of toxicity were used. One
wNas death due to the drug, occurring 5-22
days after administration, the earlier deaths
following the largerdoses. The second measure
was fractional weight change over the 11
days after drug administration. Groups of
mice were weighed on Days 0, 1, 4, 6, 8 and
11. The total weight of each group was
normalized to 1I0 on Day 0 and the area
between the group's weight curve and the
wN-eight = 1 axis calculated, areas below the
axis being taken as negative in terms of
weight change and areas above being taken
as positive. The resultant area was expressed
as a fraction ofthe total area below the weight
=1 axis. This method of calculation smooths
out errors due to daily fluctuations in weight.
Results of treatment were classified as:
(1) Progressive tumour growth.
(2) Substantially slowed or stationaiy
growth or temporary regression, followed by
resumed growth, generally after 30-40 days.
(3) Complete regression, in which the
tumour become impalpable (usually in 2-3
weeks) did not recur over a period of 60-80
days, and was undetectable at postmortem
examination.
(4) Death due to drug toxicity.
RESUTLTS
WVhen WB 4325 was given in oil,
fractional weight loss increased almost
linearly with dose, reaching -0-25 with
the largest dose (8 mg/kg) (Figure). Doses
above 4 mg/kg were in the lethal range,
and the 21-day LD50 was 6-7 mg/kg.
In contrast, when the drug was given in
liposomes, there was little toxicity.
Treated mice gained no weight over the
11-day period, whereas untreated mice
had a small fractional rise of 0 04-0*05.
This small degree of toxicity was not dose-
related over a 4-fold range. No deaths
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Dose of WB4325 3/kg)
FIGuRE.-Anti-tumour and toxic effects of
WB4325: % of complete regres-
sions, drug in oil; -0-0- % of complete
regressions, drug in liposomes; -----
fractional weight change, drug in oil,
--0-- *-- fractional weight change,
drug in liposomes.
were attributable to drug toxicity when
WB 4325 was given in liposomes, even
at the maximum dose of 41 mg/kg.
Both methods of giving the drug were
effective therapeutically. Effects were
rather erratic in the liposome-treated
group, which probably reflects the small
numbers ofanimals pergroup. Itis evident
that complete regression of most tumours
was only obtained with the drug in oil
within the dose range causing substantial
weight loss and near to the lethal range,
whereas the drug given in liposomes
produces equal therapeutic effects at
doses causing no material toxicity (Table).
DISCUSSION
A claim that one treatment is thera-
peutically more efficient than another
implies that it has a greater therapeutic
effect for the same toxicity, or that, for
the same therapeutic effect, its toxicity
is less. This comparison does not depend
on the achievement of strict equality of
either effect. When therapeutic and toxic
effects are not confounded in the same
measurement (see below), it is assumed
that they both increase with dose, and the
comparison is made by interpolation
between, or extrapolation from, observed
effects.
The simplest way to compare treat-
ments is to measure therapeutic effect
and toxicity separately. This was at-
tempted by Rahman et al. (1974), who
found that a dose of 0*75 mg/kg actino-
mycin D incorporated in liposomes pro-
longed the survival of mice with Ehrlich
ascites tumour by about 10 days, whereas
the same dose of free drug produced a
small and insignificant reduction in sur-
vival time. In contrast, whereas the LD50
of free actinomycin was 0 43 mg/kg (i.v.)
or 0 59 mg/kg (i.p.) no deaths occurred
when the liposome-encapsulated drug was
given in dose of 1 mg/kg (i.v.) or 2 mg/kg
(i.p.). There was thus evidence that
liposome incorporation was therapeuti-
cally advantageous at the single dose-
level tested. Unfortunately, the dose
chosen was materially greater than the
LD50 for the free drug, and smaller doses
of the free drug might well have given
longer survival, so that this does not
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constitute a fair comparison of free an(d
enitrapped drug.
The stuidy of Kaye et at. (1980) did
not suffer from this defect. The effects
of free and encapsulated actinomycin
were measured over a range of doses,
and it was found that encapsulation
reduced not only lethality but also
therapeutic effect (reduction of tumour
weight).
Kaye et al. (1980) also studied the effects
of liposome entrapment on the effect of
methotrexate in a range of doses. Both
anti-tumour effect and host lethality were
increased to the same extent, giving no
therapeutic advantage.
An alternative to separate measure-
ments of toxic and therapeutic effects
is measurement of the effect of treatment
on life-span in animals with lethal tumours.
As drug dose increases, survival time
first increases due to the anti-tumour
effect, reaches a peak, and then falls
due to drug toxicity. Thus, therapeutic
effect and toxicity are comprehended in
the same measurement. This procedure
is convenient and is widely used for meas-
uring the mis-called "therapeutic synergy"
(Berenbaum, 1981) but it carries a penalty.
It may be difficult, and is sometimes
impossible, to distinguish with confidence
between deaths due to the tutmour and
those due to toxicity, except near the
ends of the dose-response curve. Thus it
is not possible to weigh therapeutic
effect against toxicity unequivocally, as
can be done when they are measured
separately. Instead, one treatment is
judged to be better than another if its
peak survival time or, indeed, any part
of its survival curve, is higher than the
peak of the other. Evidently, stuch com-
parisons cannot be made for a single
(lose-level of drug (Gregoriadis & Neerun-
jun, 1975; MayheN et al., 1976: Kedar
et al. , 1981).
Measuirements of survival time over a
range of doses were made by Kobayashi
et al. (1975), Kimelberg & Atchison (1978)
and Ganapatihi et al. (1980). Kobayashi
et at. and Ganapathi et al. found more
56
or less well-defined peaks in survival time
when mice with L1210 leukaemia were
treated with cytosine arabinoside in lipo-
somes. However, the doses of free drug
were restricted to the rising part of the
dose-response curve, and the peak effect
was not determined. Thus the conclusion
cannot be drawn from these experiments
that it is advantageous to give cytosine
arabinoside in liposomes.
Kimelberg & Atchison (1978), using
methotrexate, studied a sufficiently wide
range of doses of free drug and drug in
liposomes, but found no therapeutic
advantage from liposome incorporation.
In fact, i.p. administration of drug-
containing liposomes was positively dis-
advantageous because of increased toxi-
city.
To sum up, there has hitherto been no
good evidence that liposome entrapment
of drugs is therapeutically advantageous
in treating tumours. In our experiments,
we measured toxicity (weight loss) sepa-
rately from therapeutic effect (tumour
regression). Both encapsulated and free
drug gave similar maximal rates of com-
plete regression (92% and 9500 res-
pectively), but the encapsulated drug did
this with negligible toxicity, whereas
the free drug did so only at the cost of
considerable weight loss. Thus liposome
entrapment conferred a clear therapeutic
advantage in this case.
Another difference between the two
dose-response curves suggests that lipo-
some entrapment may be advantageous,
though it does not bear strictly on the
question of therapeutic efficiency as de-
fined here. At the optimum dose level of
the free drug, a snmall increase in dose
causes deaths from toxicity. In contrast,
the optimum dose of the encapsulated
drug covers a wide range, which may be
even wider than those experiments show-
ed, as increasing the dose caused no
material toxicity up to our maximum
dose. Thus, in a sense, treatment with the
drug in liposomes is a less precarious
affair, a consideration that would be
clinicallv important.
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Studies of the pharmacokinetics of
the drug given in the 2 forms may
throw light on the mechanisms of these
effects. They are possibly associated with
the highly hydrophobic nature of the
drug, and investigation of other drugs
with similar solubility properties may be
rewarding.
We are indebted to the Medical Research Council
and Cancer Research Campaign for support, and to
Ward Blenkinsop Ltd for a gift of WB 4325.
REFERENCES
BATZRI, S. & KORN, E. D. (1973) Single layer lipo-
somes prepared with sonication. Biochem. Biophys.
Acta,298, 1015.
BERENBAUM, M. C. (1981) Criteria for analysing
interactions between biologically active agents.
Adv. Cancer Res., 35, 269.
BERENBAUM, M. C., COPE, WV. A. & DOUBLE, J. A.
(1973) The effect of microsomal enzyme inhibition
on the immunosuppressive and toxic effects of
cyclophosphamide. Clin. Exp. Immunol., 14, 257.
GANAPATHI, R., KRISHNAN, A., WODINSKY, I.,
ZUBROD, C. G. & LESKO, L. J. (1980) Effect of
cholesterol content on anti-tumor activity and
toxicity of liposome-encapsulated 1-P-D-arabino-
furanosylcytosine in vivo. Cancer Res., 40, 630.
GREGORIADIS, G. & NEERUNJUN, E. D. (1975)
Treatment of tumour bearing mice with liposome-
entrapped actinomycin D prolongs their survival.
Res. Commun. Chem. Pathol. Pharmacol., 10, 351.
HOPWOOD, WV. J. & STOCK, J. A. (1971) The effect
of macromolecules upon the rates of hydrolysis
of aromatic nitrogen mustard derivatives. Chem.
Biol. Interact., 4, 31.
KAYE, S. B., BODEN, J. A. & RYMAN, B. E. (1980)
The effect of liposome (phospholipid vesicle)
entrapment of actinomycin D and methotrexate
on the in vivo treatment of sensitive and resistant
solid murine tumors. Eur. J. Cancer, 17, 279.
KEDAR, A., MAYHEW, E. G., MOORE, R. H. &
MURPHY, G. P. (1981) Failure of actinomycin D
entrapped in liposomes to prolong survival in
renal cell adenocarcinoma-bearing mice. Oncology.,
38, 311.
KIMELBERG, H. K. & ATCHISON, M. L. (1978)
Effects of entrapment in liposomes on the distri-
butioil, degradation and effectiveness of metho-
trexate in vivo. Ann. N.Y. Acad. Sci., 308, 395.
KOBAYASHI, T., TSUKAGOSHI, S. & SAKURAI, Y.
(1975) Enhancement of the cancer chemothera-
peutic effect of cytosine arabinoside entrapped in
liposomes in mouse leukemia L1210. Gann, 66, 719.
MAYHEW, E., PAPAHADJOPOULOS, D., RUSTUM,
Y. M. & DAVE, C. (1976) Inhibition of tumor
cell growth in vitro and in vivo by 1-fi-D-arabino-
furanosylcytosine entrapped within phospholipid
vesicles. Cancer Res., 36, 4406.
RAHMAN, Y. E., CERNY, E. A., TOLLAKSEN, S. L.,
WRIGHT, B. J., NANCE, S. L. & THOMSON, J. F.
(1974) Liposome-encapsulated actinomycin D:
Potential in cancer chemotherapy. Proc. Soc. Exp.
Biol.Med., 146,1173.